Overcoming the Challenge of Maintaining Weight Reduction - Video
Overview
In this video, Dr Carel Le Roux, Clinician Scientist at University College Dublin, explains the challenge of maintaining weight reduction in people living with obesity, noting that biological adaptations can promote weight regain after weight loss1.
He highlights findings from the SURMOUNT-MAINTAIN study2, where continued tirzepatide treatment helped maintain weight reduction over two years. Patients continuing the maximum tolerated dose maintained 100% of their initial weight loss, while those reducing the dose to 5 mg maintained 70.5%. Continued treatment was also associated with sustained improvements in waist circumference, blood pressure, and HbA1c. Gastrointestinal adverse events were the most frequently reported and were generally mild to moderate, particularly during dose escalation2.
References:
1) Nota MHC, Vreeken D, Wiesmann M, Aarts EO, Hazebroek EJ, Kiliaan AJ. Obesity affects brain structure and function- rescue by bariatric surgery? Neurosci Biobehav Rev. 2020 Jan;108:646-657. doi: 10.1016/j.neubiorev.2019.11.025. Epub 2019 Nov 30. PMID: 31794778.
2) Horn D, Aronne L, Wharton S et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial The Lancet, 2026; 407, 2305-2318
Therapeutic indication:
Type 2 diabetes mellitus
•as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
•in addition to other medicinal products for the treatment of diabetes.
Weight management
• ≥30 kg/m2 (obesity) or
• ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
For Tirzepatide Prescribing Information, please check: https://image.mc.lilly.com/lib/fe9312747462077971/m/1/0e04e051-5fa2-445b-850d-4f09ef66d35e.pdf
Disclaimer:
This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.
Mounjaro®, KwikPen® and Lilly are registered trademarks of Eli Lilly and Company. To be sold by retail under prescription of Endocrinologist or Internal Medicine Specialists only. For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com. For further Information about Lilly and Lilly products please contact us at the below address: Atrium Place, 11th Floor, Tower B, Block C, Vanijya Nikunj, Phase V, Udyog Vihar, Sector 19, Gurugram, Haryana 122016, India Ph.: +91-124-4753000/01 | www.lilly.com/in.
CMAT-47561 | 16/08/2026
© 2026 Eli Lilly and Company. All Rights Reserved
Eli Lilly Privacy Policy: https://privacynotice.lilly.com/global/
